Patents Assigned to The Scripps Research Institute
  • Publication number: 20030187244
    Abstract: The invention features a G protein-coupled receptor that has an enlarged extracellular loop between the fourth and fifth transmembrane domains. A nucleic acid encoding the receptor was isolated from a human granulocytic cell library and antibodies generated against the polypeptide revealed expression in a variety of tissues including heart, placenta, and lung. This antibody, or others that specifically bind the G protein-coupled receptor of the invention, can be used in the diagnosis of diseases or conditions that are associated with upregulation of the receptor, as occurs, for example, when hematopoietic cells differentiate. These diseases include inflammatory and neurological diseases, particularly Alzheimer's Disease. The nucleic acids, polypeptides, and antibodies described herein can also be used as therapeutic agents to treat these diseases by inhibiting the expression or activity of the receptor. They can also be used in the treatment of obesity.
    Type: Application
    Filed: February 14, 2003
    Publication date: October 2, 2003
    Applicant: The Scripps Research Institute
    Inventor: Richard D. Ye
  • Publication number: 20030187247
    Abstract: The present invention describes human monoclonal antibodies which immunoreact with and neutralize human immunodeficiency virus (HIV). Also disclosed are immunotherapeutic and diagnostic methods of using the monoclonal antibodies, as well as cell line for producing the monoclonal antibodies.
    Type: Application
    Filed: December 12, 2001
    Publication date: October 2, 2003
    Applicant: The Scripps Research Institute
    Inventors: Dennis R. Burton, Carlos F. Barbas, Richard A. Lerner
  • Publication number: 20030186322
    Abstract: The invention describes the display of exogenous polypeptides on filamentous phage using a fusion between the exogenous polypeptide and phage pVII or pIX proteins. In particular, phage particles and phagemid vectors are described for expression and display of heterodimeric proteins such a antibody Fv heterodimers in combinatorial libraries, and uses thereof.
    Type: Application
    Filed: August 14, 2002
    Publication date: October 2, 2003
    Applicant: The Scripps Research Institute
    Inventors: Kim D. Janda, Peter Wirsching, Richard A. Lerner, Changshou Gao
  • Publication number: 20030175921
    Abstract: The present invention provides antibody targeting compounds in which the specificity of the antibody has been reprogrammed by covalently or noncovalently linking a targeting agent to the combining site of an antibody. By this approach, the covalently modified antibody takes on the binding specificity of the targeting agent. The compound may have biological activity provided by the targeting agent or by a separate biological agent. Various uses of the invention compounds are provided.
    Type: Application
    Filed: October 22, 2002
    Publication date: September 18, 2003
    Applicant: The Scripps Research Institute
    Inventors: Carlos F. Barbas, Christoph Rader, Subhash C. Sinha, Richard Lerner
  • Publication number: 20030176666
    Abstract: Peptides and polypeptides found in the hypothalamus region of the mammalian brain are described, particularly hypocretin polypeptides and their uses. Hypocretin polypeptides are biologically active and produce electrical changes in neurons, lower body temperature, and reduce food intake.
    Type: Application
    Filed: December 12, 2000
    Publication date: September 18, 2003
    Applicant: The Scripps Research Institute
    Inventors: J. Gregor Sutcliffe, Kaare M. Gautvik, Luis De Lecea, Floyd E. Bloom, Patria E. Danielson, Vigdis T. Gautvik, Thomas S. Kilduff, Pamela E. Foye
  • Publication number: 20030176334
    Abstract: The present invention describes methods for inhibition of angiogenesis in tissues using vitronectin &agr;v&bgr;3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using therapeutic compositions containing &agr;v&bgr;3 antagonists.
    Type: Application
    Filed: April 2, 2002
    Publication date: September 18, 2003
    Applicant: The Scripps Research Institute
    Inventors: Peter Brooks, David A. Cheresh
  • Publication number: 20030172407
    Abstract: The present invention relates to expression and assembly of foreign multimeric proteins—e.g., antibodies—in plants, as well as to transgenic plants that express such proteins. In one of several preferred embodiments, the generation and assembly of functional secretory antibodies in plants is disclosed. The invention also discloses compositions produced by the transgenic plants of the present invention and methods of using same.
    Type: Application
    Filed: February 27, 2003
    Publication date: September 11, 2003
    Applicant: The Scripps Research Institute
    Inventors: Mich B. Hein, Andrew Hiatt
  • Publication number: 20030171538
    Abstract: Peptides are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against hepatitis B virus antigens. The peptides are derived from regions of HBV polymerase, and are particularly useful in treating or preventing HBV infection, including methods for stimulating the immune response of chronically infected individuals to respond to HBV antigens.
    Type: Application
    Filed: February 5, 2003
    Publication date: September 11, 2003
    Applicant: The Scripps Research Institute
    Inventor: Francis V. Chisari
  • Publication number: 20030167534
    Abstract: The present invention relates to expression and assembly of foreign multimeric proteins—e.g., antibodies—in plants, as well as to transgenic plants that express such proteins. In one of several preferred embodiments, the generation and assembly of functional secretory antibodies in plants is disclosed. The invention also discloses compositions produced by the transgenic plants of the present invention and methods of using same.
    Type: Application
    Filed: February 25, 2003
    Publication date: September 4, 2003
    Applicant: The Scripps Research Institute
    Inventors: Mich B. Hein, Andrew Hiatt
  • Publication number: 20030166871
    Abstract: A humanized murine antibody is provided. The amino acid sequences of a light chain complementarity determining region from a mouse antibody are grafted onto a human light chain, and a heavy chain complementarity determining region from a mouse antibody are grafted onto a human antibody heavy chain to produce libraries from which a humanized murine antibody having the desired specificity is selected.
    Type: Application
    Filed: February 19, 2002
    Publication date: September 4, 2003
    Applicant: The Scripps Research Institute
    Inventors: Carlos F. Barbas, Christoph Rader
  • Publication number: 20030165837
    Abstract: A simple, nondestructive, and high throughput method for establishing DNA binding affinity and sequence selectivity is based on the loss of fluorescence derived from the displacement of ethidium bromide or thiazole orange from the DNA of interest or, in selected instances, the change in intrinsic fluorescence of a DNA binding agent itself. The method is applicable for assessing relative or absolute DNA binding affinities. Enlisting a library of hairpin deoxyoligonucleotides containing all 5 base pair (512 hairpins) or 4 base pair (136 hairpins) sequences displayed in a 96-well format, a compound's rank order binding to all possible sequences is generated resulting in a high resolution definition of its sequence selectivity using this fluorescent intercalator displacement (FID) assay. As such, the technique complements the use of footprinting or affinity cleavage for the establishment of DNA binding selectivity and provides the information at a higher resolution.
    Type: Application
    Filed: May 25, 2001
    Publication date: September 4, 2003
    Applicant: The Scripps Research Institute
    Inventor: Dale L. Boger
  • Patent number: 6613734
    Abstract: The present invention discloses useful surfactant molecules including polypeptides, proteins, and a variety of other organic molecules, as well as methods of making and using same. Surfactant compositions, including liposomal surfactant compositions, are also disclosed. In one preferred embodiment, a pulmonary surfactant composition comprises one or more pharmaceutically acceptable phospholipids admixed with a polypeptide comprising about 10 to 60 amino acid residues, wherein the polypeptide includes a sequence constituted by alternating groupings of charged amino acid residues and uncharged amino acid residues.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 2, 2003
    Assignee: The Scripps Research Institute
    Inventors: Charles G. Cochrane, Susan D. Revak
  • Patent number: 6613875
    Abstract: Cyclic homodetic peptides having a repeating D-L-chirality motif are shown to have a stable disk conformation with the amino acid side chains extending radially outward and the carbonyl and amino groups extending axially upward or downward. Such cyclic peptides can be employed as subunits in the assembly of molecular tubes. Cyclic peptides having a repeating D-L-chirality motif and lacking mutually repulsive side-chains are shown to stack atop one another in an anti-parallel fashion and are shown to be held together by the formation of &bgr;-sheet hydrogen bonding. The stacked cyclic peptides form a molecular tube having a central channel. The diameter of the channel is determined by the size cyclic peptide. If the cyclic peptide includes ionizable amino acid residues, e.g. glutamic acid or lysine, assembly and disassembly of the molecular tubes can be controlled by varying the pH. If the cyclic peptide includes hydrophobic amino acid residues, the molecular tube will insert into a lipid membrane.
    Type: Grant
    Filed: April 15, 1996
    Date of Patent: September 2, 2003
    Assignee: The Scripps Research Institute
    Inventor: Reza M. Ghadiri
  • Patent number: 6610512
    Abstract: Zinc finger-nucleotide binding polypeptides having binding specificity for target nucleotides containing one or GNN triplets are provided. Compositions containing such polypeptides and the use of such polypeptides and compositions for regulating gene expression are also provided.
    Type: Grant
    Filed: January 28, 2000
    Date of Patent: August 26, 2003
    Assignee: The Scripps Research Institute
    Inventor: Carlos F. Barbas
  • Patent number: 6607727
    Abstract: Peptides are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against hepatitis B virus antigens. The peptides are derived from regions of HBV polymerase, and are particularly useful in treating or preventing HBV infection, including methods for stimulating the immune response of chronically infected individuals to respond to HBV antigens.
    Type: Grant
    Filed: May 20, 1996
    Date of Patent: August 19, 2003
    Assignee: The Scripps Research Institute
    Inventors: Francis V. Chisari, Carlo Ferrari, Amalia Penna, Gabriele Missael
  • Publication number: 20030148448
    Abstract: This invention provides novel genes and polypeptides of the sweet receptor family, methods for production of the polypeptides, methods for screening compounds that specifically bind to and/or modulate the activity of these polypeptides; and antibodies specific for the polypeptides.
    Type: Application
    Filed: September 17, 2002
    Publication date: August 7, 2003
    Applicants: IRM, LLC, The Scripps Research Institute
    Inventors: Jiayu Liao, Sheng Ding, Peter G. Schultz
  • Publication number: 20030143582
    Abstract: The present invention provides compositions including polypeptides useful for regulating the cell cycle, proliferation, tumorigenesis, and genomic stability, mutants of such polypeptides useful in identifying abnormal cells and diagnosing disease, antibodies useful for identifying the polypeptides, and polynucleotides that encode the polypeptides.
    Type: Application
    Filed: September 16, 2002
    Publication date: July 31, 2003
    Applicant: The Scripps Research Institute
    Inventors: Steve Reed, Charles Spruck, Heimo Strohmaier, Olle Sangfelt
  • Publication number: 20030138420
    Abstract: The present invention provides a method for inhibiting tissue factor (TF) mediated reperfusion tissue damage in a subject.
    Type: Application
    Filed: August 12, 2002
    Publication date: July 24, 2003
    Applicant: The Scripps Research Institute
    Inventor: Gregory J. del Zoppo
  • Publication number: 20030138946
    Abstract: The present invention relates to synthetic antigen-presenting matrices, their methods of making and their methods of use. One such matrix is cells that have been transfected to produce MHC antigen-presenting molecules and assisting molecules such as co-stimulatory molecules. The matrices can be used to activate CD8+ T-cells to produce cytokines and become cytotoxic.
    Type: Application
    Filed: October 8, 2002
    Publication date: July 24, 2003
    Applicant: The Scripps Research Institute
    Inventors: Zeling Cai, Jonathan Sprent, Anders Brunmark, Michael Jackson, Per A. Peterson, Alain Luxembourg, Didier J. Leturcq, Ann M. Moriarty
  • Patent number: 6596484
    Abstract: An improved method for the simultaneous sequence-specific identification of mRNAs in a mRNA population allows the visualization of nearly every mRNA expressed by a tissue as a distinct band on a gel whose intensity corresponds roughly to the concentration of the mRNA. In general, the method comprises the formation of cDNA using anchor primers to fix a 3′-endpoint, producing cloned inserts from the cDNA in a vector containing a bacteriophage-specific promoter for subsequent RNA synthesis, generating linearized fragments of the cloned inserts, preparing cRNA, transcribing cDNA from the cRNA using a set of primers, and performing PCR using a 3′-primer whose sequence is derived from the vector and a set of 5′-primers that is derived from the primers used for transcription of cDNA from cRNA. The method can identify changes in expression of mRNA associated with the administration of drugs or with physiological or pathological conditions.
    Type: Grant
    Filed: August 29, 2000
    Date of Patent: July 22, 2003
    Assignee: The Scripps Research Institute
    Inventors: J. Gregor Sutcliffe, Mark G. Erlander, Karl W. Hasel